Targacept, Inc. Presents at BIO 2001 International Investor and Partnering Forum
Winston-Salem, NC
June 25, 2001
Targacept, Inc., a privately held pharmaceutical research and development company, will present an update of the company's progress at BIO 2001 International Investor and Partnering Forum in San Diego.
| WHO: | J. Donald deBethizy, Ph.D. |
| President and Chief Executive Officer | |
| Targacept, Inc. | |
| WHEN: | June 27, 2001 at 2:00 p.m. |
| WHERE: | BIO 2001 International Convention & Exhibition |
| San Diego Convention Center | |
| Room A | |
| San Diego, CA |
A copy of Dr. deBethizy’s presentation materials will be made available on the company’s web site: www.targacept.com.
Download the presentation: targaceptoverview6_27.ppt
Right-click on the link above and choose "Save Target As..." to download the file to disk.
Targacept is focused on the discovery and development of neuronal nicotinic receptor-based therapies for neurodegenerative, neuropsychiatric and gastrointestinal diseases. The company has products in research and development for treating Alzheimer’s disease, Parkinson’s disease, ulcerative colitis, depression, pain, attention deficit disorder and Tourette’s syndrome, among others.
Targacept was established in 1997 as a wholly owned subsidiary of R.J. Reynolds Tobacco Company (NYSE: RJR). It was spun out in August 2000, in one of the largest ($30.4 million) first-round venture capital financings in U.S. biotech history and the largest in North Carolina biotech history. The company has strategic alliances with Aventis Pharmaceuticals of Strasbourg, France and Dr. Falk Pharma of Freiburg, Germany to develop and commercialize Targacept compounds.
Additional information is available for download.
Back to Newsroom